Biotech Values

[oc631]

Were you perhaps unduly skeptical of ABT’s HCV claims back in October?

The results today were much better than I expected. This throws a monkey-wrench into the theory that a nucleotide-backbone is required for oral therapy. Let's see if the SVR rate from the CO-PILOT study holds throughout the 12-week follow-up period.